ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

With EMPACT-MI being presented at ACC, the definitive study of an additional agent (empagliflozin) will allow for a great discussion on options for patients who have acute MI and evidence of heart failure. 

In this interview, Schuyler Jones, MD FACC, and Purvi Parwani, MBBS, MPH, FACC discuss Not the Same Old 5...

High levels of Lp(a) impact approximately 1 in 5 individuals globally, signaling an elevated risk of heart attacks, strokes, and valve disease. How should clinicians navigate this challenge, given the current lack of specific treatment options? 

 In this interview, Raul Santos MD, PhD, and Sun Moon Kim MD, FACC...

Understanding the etiology of left ventricular hypertrophy is increasingly important due to the increasing number of targeted therapies coming online. This discussion provides a high-level approach to differentiating important causes of increased wall thickness. 

 In this interview, Timothy C. Wong, MD, MS, FACC and...

Incorporating spiritual evaluation into medical science is worth consideration. The presence of edifying emotions can potentially yield positive effects on hypertension treatment outcomes. 

In this interview, Maria Emília Figueiredo Teixeira, MD, PhD and Sidney C. Smith Jr., MD, MACC discuss the primary findings...